iiinova — where your digital self keeps evolving

Reposted by Mina Hosseini

Mary Guy @maryjguy.bsky.social · 01/03/2026

Really enjoyed the discussions of the recent @euhealthgov.bsky.social webinar (and also contributing to the Symposium!) Webinar: www.youtube.com/watch?v=RHmj... Write-up: healthgovernance.ideasoneurope.eu/2026/02/27/s...

youtube.com

EUHealthGov: ‘Public Health, Markets, and Law’, a Symposium in the Journal of Law, Medicine & Ethics

YouTube video by UACES

032

Reposted by Mina Hosseini

EUHEALTHGOV @euhealthgov.bsky.social · 12/01/2026

Our first webinar of 2026 is a launch of the @jlme-journal.bsky.social "Public Health, Markets, and Law" Symposium We're delighted to welcome the guest editors & the contributors to present overviews of their papers Join us on Tuesday 24 February at 15:00 GMT! euhealthgov.org/launch-publi...

euhealthgov.org

Launch: ‘Public Health, Markets, and Law’, a Symposium in the Journal of Law, Medicine, and Ethics – EU Health Governance Network

042

Reposted by Mina Hosseini

Mary Guy @maryjguy.bsky.social · 15/09/2025

Delighted to see this Symposium of @jlme-journal.bsky.social on Public Health, Markets, and Law is now out. Many thanks to @minacompetition.bsky.social and Imelda Maher! My article considers #hospitals #stateaid and #SGEI www.cambridge.org/core/journal...

043

Reposted by Mina Hosseini

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · 15/09/2025

The September issue of the Journal of Law, Medicine & Ethics is now online. This issue features the open-access symposium Public Health, Markets, and Law, guest edited by @minacompetition.bsky.social and Imelda Maher, with incisive, in-depth articles. Read now: www.cambridge.org/core/journal...

033

Reposted by Mina Hosseini

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · 03/09/2025

New open-access on FirstView: "EU’s Extraterritorial Obligations for Global Medicine Access Under the Convention on the Rights of Persons with Disability (CPRD)" by ‪@katperehudoff.bsky.social‬ from special issue "Public Health, Markets, and Law." #DisabilityRights www.cambridge.org/core/journal...

Symposium Articles
EU’s Extraterritorial Obligations for Global Medicine Access Under the
Convention on the Rights of Persons with Disability (CPRD)
Katrina Perehudoff1,2,3,4,5
1University of Amsterdam Amsterdam Law School, Law for Health and Life, Netherlands; 2Amsterdam Institute for Global Health and Development, Netherlands;
3Amsterdam Centre for European Studies, University of Amsterdam; 4Amsterdam Centre for European Law and Governance, University of Amsterdam and 5Medicines
Law & Policy, Amsterdam, the Netherlands
Abstract
Equitable access to medicines is vital for people with disabilities to receive effective, affordable, and quality treatment, helping preserve
functionality, prevent further disability, and promote social and economic inclusion. This paper explores the specific medicine needs of people
with disabilities in low- and middle-income countries (LMICs), focusing on the European Union’s (EU) extraterritorial legal obligations under
the Convention on the Rights of Persons with Disabilities (CRPD). As the first regional international organization to accede to a UN human
rights treaty, the EU offers a unique case for examining how international legal commitments extend beyond its borders. The paper outlines a
legal framework based on the CRPD to assess the EU’s responsibilities for ensuring access to medicines globally. This framework is applied to
two case studies: the EU’s internal joint COVID-19 vaccine procurement strategy and its external BioNTainer initiative for vaccine production
in Africa under Team Europe. The analysis finds that the EU falls short of its CRPD obligations, particularly in areas of technology transfer and
intellectual property sharing, which are essential for equitable global vaccine access. The paper concludes that the EU’s current actions do not
fulfill its human rights commitments to people with disabilities in LMICs.
Keywords: access to medicines; disability rights; pharmaceuticals; European Union; intellectual property

031

Reposted by Mina Hosseini

EUHEALTHGOV @euhealthgov.bsky.social · 03/09/2025

Day 2 #UACES2025 saw our 3rd panel on data exclusivity vouchers, global health, wellness devices, and solidarity in European healthcare! Many thanks to Paula Dornbusch, Ian Manners, Federica Casarosa and Mary Guy

041

Reposted by Mina Hosseini

EUHEALTHGOV @euhealthgov.bsky.social · 03/09/2025

Our final panel at #UACES2025 considered the balance between health and other EU policies - ethics, trade, alcohol brand marketing, and AI. Many thanks to Juan Collado Perez Llantada, @merikoivusalo.bsky.social, Jaydon Souter, and Phil Ryan!

052

Reposted by Mina Hosseini

EUHEALTHGOV @euhealthgov.bsky.social · 02/09/2025

We’re having a great time at #UACES2025! Day 1 included presentations on complexity, Covid-19, competition law, cross-border telemedicine and forced migrants’ access to health and healthcare Many thanks @eleanorbrooks.bsky.social @minacompetition.bsky.social @mechthildroos.bsky.social & others!

041

Reposted by Mina Hosseini

Mary Guy @maryjguy.bsky.social · 31/08/2025

Grand #UACES2025 walking tour of Liverpool this afternoon - taking in reconciling the city’s slave trade history, football, and a certain boyband… Thanks Lauren for the group photo!

041

Reposted by Mina Hosseini

Anniek de Ruijter @deruijter.bsky.social · 14/08/2025

With @PramitiParwani & @katperehudoff.bsky.social, we explored EU pharma regulators’ role in access to medicines in low-income countries. Trust remains one-way, reinforcing dependencies; building regional regulatory capacity is key for global health 💫

042

Reposted by Mina Hosseini

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · 13/08/2025

New open access on FirstView: "Trust Beyond Borders: European External Regulatory Influence on Access to Medicines" by Pramiti Parwani, ‪@katperehudoff.bsky.social‬, and @deruijter.bsky.social from the upcoming fall special issue "Public Health, Markets, and Law." www.cambridge.org/core/journal...

Symposium Articles
Trust Beyond Borders: European External Regulatory Influence on
Access to Medicines
Pramiti Parwani1,2,3 , Katrina Perehudoff1,2,3 and Anniek de Ruijter1,2
1University of Amsterdam, Amsterdam Law School, Law for Health and Life, Netherlands; 2Amsterdam Institute for Global Health and Development, Netherlands and
3Amsterdam Centre for European Law and Governance, University of Amsterdam, Netherlands
Abstract
European institutions are widely recognized as wielding regulatory power in a globalized market, exporting its standards across borders and
between sectors. This paper asks what institutional dynamics catalyze European external regulatory impact on pharmaceutical governance in
low- and middle-income countries (LMICs). The research focuses on two European regulatory bodies, the European Medicines Agency (EMA)
and the European Patent Office (EPO), and explores the dynamics of their technocratic outreach beyond European borders. We find that trust
is a key underlying institutional dynamic facilitating some forms of European external relations. The agencies extend their influence through
technical assistance, collaboration, and work-sharing with LMIC regulators, fostering a one-sided relationship of“technocratic trust.” This
trust, reinforced by international regulatory frameworks that position the EMA and EPO as“trustworthy” regulators, enables these agencies to
expand their regulatory influence beyond Europe. By critically examining the impact of this trust-building on LMICs’ regulatory autonomy,
this research contributes to the broader discourse on European regulatory power in global health governance and highlights potential
implications for pharmaceutical markets and access in LMICs.
Keywords: European Regulatory Bodies; Pharmaceuticals Access; European Medicines Agency (EMA); European Patent Office (EPO); Trust

052

Reposted by Mina Hosseini

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · 30/07/2025

New open-access on FirstView: "Abuse of Dominant Position, Effective Judicial Protection and Abuse of Procedure" by Carmen de Vivero de Porras and Enrique Sanjuán y Muñoz analyzes the attempt to keep a generic alternative to NuvaRing out of the market. www.cambridge.org/core/journal...

Symposium Articles
Abuse of Dominant Position, Effective Judicial Protection and Abuse
of Procedure
Carmen de Vivero de Porras and Enrique Sanjuán y Muñoz
School of Law, University of Malaga, Spain
Abstract
On October 21, 2022, the Spanish Competition Agency (CNMC) sanctioned the North American pharmaceutical company Merck Sharp &
Dohme for abuse of a dominant position. The practice for which it was finally sanctioned consisted of the adoption of a strategy aimed at
delaying and making it difficult for another company to enter the Spanish medicines market in order to protect sales for a product marketed
exclusively by that company and for which had a patent. This paper analyzes this resolution in an attempt to delimit the difference between the
legitimate exercise of the right to effective judicial protection and its abuse.
Keywords: competition; strategy; medicines market; dominant position; market

062

Reposted by Mina Hosseini

Susi Geiger @susigeiger.bsky.social · 29/07/2025

Fascinated by #ElizabethHolmes of #Theranos and her wild journey from digital health entrepreneur heroine to villaine and #Girlboss? Asking yourself in whose interest it all happened? So were we! @keanbirch.bsky.social @provokedeconomy.bsky.social @allartmarkets.bsky.social you might like this one

183

Reposted by Mina Hosseini

Mary Guy @maryjguy.bsky.social · 25/07/2025

Proud to share this new publication on #hospitals #stateaid and #SGEI in the excellent Symposium on “Public Health, Markets, and Law” with @jlme-journal.bsky.social edited by Dr Mina Hosseini and Imelda Maher. Some key findings follow! www.cambridge.org/core/journal...

cambridge.org

On The Quiet Power of National Decisions: Hospitals, State Aid, and Services of General Economic Interest | Journal of Law, Medicine & Ethics | Cambridge Core

On The Quiet Power of National Decisions: Hospitals, State Aid, and Services of General Economic Interest

154

Reposted by Mina Hosseini

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · 25/07/2025

New open access article on FirstView: "Competition Law and Ethics of Innovation as Catalysts for Fairness: Reimagining the EU’s COVID-19 Vaccine Strategy" by @minacompetition.bsky.social, part of the upcoming symposium "Public Health, Markets and Law." www.cambridge.org/core/journal...

Symposium Articles
Competition Law and Ethics of Innovation as Catalysts for Fairness:
Reimagining the EU’s COVID-19 Vaccine Strategy
Mina Hosseini
Sutherland School of Law, University College Dublin, Ireland
Abstract
The“EU Vaccines Strategy” launched by the European Commission in June 2020 aimed to ensure vaccine safety, equitable access, affordability,
swift distribution, and global solidarity for COVID-19 vaccines. This study critiques the Commission’s centralized procurement approach,
focusing on Advance Purchase Agreements (APAs) through a literature review, policy analysis, and a case study of the EU-AstraZeneca’s APA.
It identifies critical challenges, including transparency deficits, accountability gaps, and anticompetitive practices by vaccine producers that
undermine equitable access. Drawing on these insights, the study proposes the FACER Framework— Fairness, Accountability, Competition
Law, Ethics of Innovation, and Resilience— a novel model integrating the Treaty on the European Union (TEU) and the Treaty on the
Functioning of the European Union (TFEU) oversight with ethical principles. By embedding legal and moral accountability, FACER offers EU
policymakers a robust tool to enhance vaccine strategy and equity in future health crises.
Keywords: Pharmaceutical Procurement; EU Vaccines Strategy; Advance Purchase Agreements; Competition Law; Ethics of Innovation

021

Reposted by Mina Hosseini

Mary Guy @maryjguy.bsky.social · 23/07/2025

Great to see this new article by @minacompetition.bsky.social in @jlme-journal.bsky.social! www.cambridge.org/core/journal...

131

Mina Hosseini @minacompetition.bsky.social · 21/07/2025

Delighted to see the first paper from our Symposium “Public Health, Markets and Law” co-edited with Professor Imelda Maher now published in @jlme-journal.bsky.social @ucdschooloflaw.bsky.social @ucddublin.bsky.social

062

Reposted by Mina Hosseini

Law Centre for Health and Life @lawhealthlife.bsky.social · 24/02/2025

Mahsa Shabani from Law for Health and Life contributed to Future-AI’s global guidelines for trustworthy AI in healthcare—now published in The BMJ! A major step toward safer, ethical AI. 🔗 Read more: bit.ly/4i4RN9d

bit.ly

Future-AI Consortium Tackle Trustworthy AI in Healthcare - LHL

We are excited to announce that Mahsa Shabani from the Law Centre for Health and Life is part of the pioneering Future-AI consortium.

041

Reposted by Mina Hosseini

Coercive In/Justice @coerciveinjustice.bsky.social · 31/01/2025

#CoerciveInJustice is now online! 🛜 Check out our new website: www.coerciveinjustice.com to learn about the research project, meet the team, and catch up on all the latest news and events.

032

Reposted by Mina Hosseini

audreymplan.bsky.social @audreymplan.bsky.social · 29/01/2025

‼️ CALL FOR PAPERS - ECRs IN IRELAND/UK ‼️ Save an #ECR, spread with your network 😉 ▶️"'Law and...' Reflections on interdisciplinarity and the law from ECAs in 🇮🇪 & 🇬🇧" 📆Dublin, Jun 12th 2025 ⏰Submissions Deadline: Apr 1st 2025

153

Reposted by Mina Hosseini

Grażyna Baranowska @grabaranowska.bsky.social · 11/02/2025

Thinking about applying for a Marie Curie fellowship this year? Join Cathryn Costello, @liliantsourdi.bsky.social, @minacompetition.bsky.social, Violeta Moreno-Lax and me next Tuesday at 12:00 CET.

065

Mina Hosseini @minacompetition.bsky.social · 13/01/2025

Delighted that our article with Imelda Maher has been nominated for Concurrences 2025 Antitrust Writing Awards. Vote for us here: awards.concurrences.com/en/awards/20...

010

Reposted by Mina Hosseini

EUHEALTHGOV @euhealthgov.bsky.social · 09/12/2024

Hello BlueSky! We’re EUHealthGov- here for EU health law and policy, working with academics, policymakers, practitioners… Check out our website for information about our events www.euhealthgov.org

euhealthgov.org

EU Health Governance Network – A network of professionals interested in EU health law and policy

1186

Reposted by Mina Hosseini

Madhu Pai, MD, PhD @madhupai.bsky.social · 07/12/2024

Two wonderful global health scholars have made their global health books free to download Bravo and thanks @seyeabimbola.bsky.social and @thewrittenro.bsky.social The Foreign Gaze: www.editions.ird.fr/open_access_... Rethinking Global Health: taylorfrancis.com/books/oa-mon...

58339

Mina Hosseini @minacompetition.bsky.social · 22/11/2024

I am happy that our chapter with Imelda Maher, 'Competition Law Institutions and Future Challenges,' has just been published as part of the landmark collection, Why Competition, by Concurrences. @ucdschooloflaw.bsky.social

020

Reposted by Mina Hosseini

UACES (University Association for Contemporary European Studies) @uaces.bsky.social · 18/11/2024

The Call for Papers for the UACES 55th Annual Conference 2025 at Liverpool John Moores University is officially open! Join us from 31 August to 3 September 2025, to explore Europe’s resilience in a changing world. Submit your paper by 26 January 2025 👉 www.conftool.org/uaces2025/ #CfP #UACES2025

02018

Mina Hosseini @minacompetition.bsky.social · 20/09/2024

The report from the #COMPHACRISIS #MSCA Finsl Workshop on 'Healthcare at the Crossroads: Regulation, Innovation, and Market Dynamics' (Sep 13, 2024, UCD) is now available! Explore key insights on EU healthcare competition and policy: zenodo.org/records/1380...

zenodo.org

Report of the COMPHACRISIS Project Final Workshop

This report summarizes the proceedings of the "Healthcare at the Crossroads: COMPHACRISIS Workshop on Regulation, Innovation, and Market Dynamics" held on September 13, 2024, at the UCD Sutherland Sch...

021

Reposted by Mina Hosseini

Steve Peers @stevepeers.bsky.social · 19/09/2024

CJEU, competition law New judgment: Booking .com clauses preventing hotels from offering rooms at lower prices on other sites are anti-competitive

25120

Mina Hosseini @minacompetition.bsky.social · 18/01/2024

It was a pleasure working with Professor Imelda Maher on a Foreword about Cooperation between national competition authorities for Concurrences e-Competitions (Antitrust Case Law e-Bulletin)

000

Mina Hosseini @minacompetition.bsky.social · 08/12/2023

The last lecture of this year was a fantastic opportunity for me to share ideas and insight with Professor Marek Martyniszyn and his LLM students at Queen's University Belfast.

030